These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 23415012

  • 1. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W.
    J Hematol Oncol; 2013 Feb 18; 6():18. PubMed ID: 23415012
    [Abstract] [Full Text] [Related]

  • 2. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.
    Blood; 2012 Sep 27; 120(13):2679-89. PubMed ID: 22826565
    [Abstract] [Full Text] [Related]

  • 3. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
    Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM.
    Leukemia; 2008 Jan 27; 22(1):147-60. PubMed ID: 17928881
    [Abstract] [Full Text] [Related]

  • 4. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M.
    Oncotarget; 2015 Nov 10; 6(35):37930-47. PubMed ID: 26473447
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.
    Mol Cancer Ther; 2010 Apr 10; 9(4):963-75. PubMed ID: 20371718
    [Abstract] [Full Text] [Related]

  • 6. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
    Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Récher C.
    Leukemia; 2013 Feb 10; 27(2):325-35. PubMed ID: 22902361
    [Abstract] [Full Text] [Related]

  • 7. SYK regulates mTOR signaling in AML.
    Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.
    Leukemia; 2013 Nov 10; 27(11):2118-28. PubMed ID: 23535559
    [Abstract] [Full Text] [Related]

  • 8. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J.
    Cell Cycle; 2015 Nov 10; 14(2):232-42. PubMed ID: 25607647
    [Abstract] [Full Text] [Related]

  • 9. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM.
    Oncotarget; 2012 Dec 10; 3(12):1615-28. PubMed ID: 23271044
    [Abstract] [Full Text] [Related]

  • 10. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.
    Blood; 2008 Jan 01; 111(1):379-82. PubMed ID: 17878402
    [Abstract] [Full Text] [Related]

  • 11. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.
    Anticancer Drugs; 2013 Oct 01; 24(9):889-98. PubMed ID: 23838676
    [Abstract] [Full Text] [Related]

  • 12. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC.
    Clin Cancer Res; 2011 Jul 01; 17(13):4378-88. PubMed ID: 21415215
    [Abstract] [Full Text] [Related]

  • 13. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.
    Leukemia; 2015 Apr 01; 29(4):828-38. PubMed ID: 25322685
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.
    PLoS One; 2013 Apr 01; 8(11):e80070. PubMed ID: 24244612
    [Abstract] [Full Text] [Related]

  • 15. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J.
    PLoS One; 2015 Apr 01; 10(7):e0132880. PubMed ID: 26176608
    [Abstract] [Full Text] [Related]

  • 16. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
    Gao Y, Gao J, Li M, Zheng Y, Wang Y, Zhang H, Wang W, Chu Y, Wang X, Xu M, Cheng T, Ju Z, Yuan W.
    J Hematol Oncol; 2016 Apr 12; 9():36. PubMed ID: 27071307
    [Abstract] [Full Text] [Related]

  • 17. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
    Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM.
    Cancer Res; 2008 Nov 15; 68(22):9394-403. PubMed ID: 19010914
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
    Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE.
    Blood; 2009 Oct 01; 114(14):2926-35. PubMed ID: 19641186
    [Abstract] [Full Text] [Related]

  • 19. Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy?
    Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan SC, Yang YJ, Gu ZP.
    Cell Biochem Biophys; 2013 Mar 01; 65(2):217-27. PubMed ID: 23015227
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW, Chen W, Liang H, Liu H, Liang C, Zhi X, Hu LQ, Yu XZ, Wei T, Ma T, Xue F, Zheng L, Zhao B, Feng XH, Bai XL, Liang TB.
    Mol Cancer Ther; 2015 Aug 01; 14(8):1805-15. PubMed ID: 26026051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.